HAEM5:Monoclonal immunoglobulin deposition disease: Difference between revisions
| [checked revision] | [checked revision] |
Bailey.Glen (talk | contribs) No edit summary |
Bailey.Glen (talk | contribs) Removed old template contents |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:Monoclonal immunoglobulin deposition disease}} | {{DISPLAYTITLE:Monoclonal immunoglobulin deposition disease}} | ||
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]] | [[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]] | ||
{{Under Construction}} | {{Under Construction}} | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Light Chain and Heavy Chain Deposition Disease]]. | ||
}}</blockquote> | }}</blockquote> | ||
| Line 37: | Line 38: | ||
|} | |} | ||
==WHO Essential and Desirable Genetic Diagnostic Criteria== | ==WHO Essential and Desirable Genetic Diagnostic Criteria== | ||
<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span> | <span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span> | ||
| Line 244: | Line 126: | ||
|} | |} | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
*There is limited information on the genomic abnormalities of the plasma cells in light chain and heavy chain deposition disease | *There is limited information on the genomic abnormalities of the plasma cells in light chain and heavy chain deposition disease | ||
| Line 256: | Line 138: | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=v4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).|Please incorporate this section into the relevant tables found in: | ||
* Chromosomal Rearrangements (Gene Fusions) | * Chromosomal Rearrangements (Gene Fusions) | ||
* Individual Region Genomic Gain/Loss/LOH | * Individual Region Genomic Gain/Loss/LOH | ||
| Line 325: | Line 207: | ||
|} | |} | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=v4:Genomic Gain/Loss/LOH|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
*Findings are similar to those of the underlying condition (e.g., [[HAEM4:Plasma Cell Neoplasms|Plasma Cell Neoplasm]], [[HAEM5:Lymphoplasmacytic lymphoma]]) | *Findings are similar to those of the underlying condition (e.g., [[HAEM4:Plasma Cell Neoplasms|Plasma Cell Neoplasm]], [[HAEM5:Lymphoplasmacytic lymphoma]]) | ||
| Line 371: | Line 253: | ||
|} | |} | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=v4:Characteristic Chromosomal Aberrations / Patterns|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
*Patients with PCM presumably have similar genomic abnormalities to myelomas without Ig deposition, perhaps with a different prevalence | *Patients with PCM presumably have similar genomic abnormalities to myelomas without Ig deposition, perhaps with a different prevalence | ||
| Line 430: | Line 312: | ||
|}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content. | |}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content. | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
*Findings are similar to those of the underlying condition (e.g., [[HAEM4:Plasma Cell Neoplasms|Plasma Cell Neoplasm]], [[HAEM5:Lymphoplasmacytic lymphoma]]) | *Findings are similar to those of the underlying condition (e.g., [[HAEM4:Plasma Cell Neoplasms|Plasma Cell Neoplasm]], [[HAEM5:Lymphoplasmacytic lymphoma]]) | ||
| Line 467: | Line 349: | ||
|} | |} | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}}</blockquote> | ||
*Findings are similar to those of the underlying condition (e.g., [[HAEM4:Plasma Cell Neoplasms|Plasma Cell Neoplasm]], [[HAEM5:Lymphoplasmacytic lymphoma]]) | *Findings are similar to those of the underlying condition (e.g., [[HAEM4:Plasma Cell Neoplasms|Plasma Cell Neoplasm]], [[HAEM5:Lymphoplasmacytic lymphoma]]) | ||
| Line 476: | Line 358: | ||
</blockquote> | </blockquote> | ||
==Genetic Diagnostic Testing Methods== | ==Genetic Diagnostic Testing Methods== | ||
Testing methods include those needed to diagnose the underlying condition, as well as those specifically needed to detect the offending Ig in liquid samples and tissues. The following methods of testing have been reported<ref name=":0" /><ref name=":2" /><ref name=":1" /><ref name=":4" /><ref name=":3" />: | Testing methods include those needed to diagnose the underlying condition, as well as those specifically needed to detect the offending Ig in liquid samples and tissues. The following methods of testing have been reported<ref name=":0">{{Cite journal|last=Pozzi|first=Claudio|last2=D'Amico|first2=Marco|last3=Fogazzi|first3=Giovanni B.|last4=Curioni|first4=Simona|last5=Ferrario|first5=Franco|last6=Pasquali|first6=Sonia|last7=Quattrocchio|first7=Giacomo|last8=Rollino|first8=Cristiana|last9=Segagni|first9=Siro|date=2003-12|title=Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors|url=https://pubmed.ncbi.nlm.nih.gov/14655186|journal=American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation|volume=42|issue=6|pages=1154–1163|doi=10.1053/j.ajkd.2003.08.040|issn=1523-6838|pmid=14655186}}</ref><ref name=":2">{{Cite journal|last=Nasr|first=Samih H.|last2=Valeri|first2=Anthony M.|last3=Cornell|first3=Lynn D.|last4=Fidler|first4=Mary E.|last5=Sethi|first5=Sanjeev|last6=D'Agati|first6=Vivette D.|last7=Leung|first7=Nelson|date=2012-02|title=Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution|url=https://pubmed.ncbi.nlm.nih.gov/22156754|journal=Clinical journal of the American Society of Nephrology: CJASN|volume=7|issue=2|pages=231–239|doi=10.2215/CJN.08640811|issn=1555-905X|pmid=22156754}}</ref><ref name=":1">{{Cite journal|last=Joly|first=Florent|last2=Cohen|first2=Camille|last3=Javaugue|first3=Vincent|last4=Bender|first4=Sébastien|last5=Belmouaz|first5=Mohamed|last6=Arnulf|first6=Bertrand|last7=Knebelmann|first7=Bertrand|last8=Nouvier|first8=Mathilde|last9=Audard|first9=Vincent|date=2019-02-07|title=Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study|url=https://pubmed.ncbi.nlm.nih.gov/30578255|journal=Blood|volume=133|issue=6|pages=576–587|doi=10.1182/blood-2018-09-872028|issn=1528-0020|pmid=30578255}}</ref><ref name=":4" /><ref name=":3">{{Cite journal|last=Mohan|first=Meera|last2=Buros|first2=Amy|last3=Mathur|first3=Pankaj|last4=Gokden|first4=Neriman|last5=Singh|first5=Manisha|last6=Susanibar|first6=Sandra|last7=Jo Kamimoto|first7=Jorge|last8=Hoque|first8=Shadiqul|last9=Radhakrishnan|first9=Muthukumar|date=2017-08|title=Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease|url=https://pubmed.ncbi.nlm.nih.gov/28383130|journal=American Journal of Hematology|volume=92|issue=8|pages=739–745|doi=10.1002/ajh.24756|issn=1096-8652|pmid=28383130}}</ref>: | ||
*Diagnosis relies on detection of monoclonal Ig deposition in tissues biopsy; fine needle aspiration is not enough for diagnosis | *Diagnosis relies on detection of monoclonal Ig deposition in tissues biopsy; fine needle aspiration is not enough for diagnosis | ||
| Line 491: | Line 373: | ||
==Additional Information== | ==Additional Information== | ||
*Survival improves with early diagnosis and proteasome inhibitor (PI)-based treatment, autologous stem cell transplantation, and kidney transplantation<ref name=":5" /><ref name=":6">{{Cite journal|last=Cohen|first=Camille|last2=Royer|first2=Bruno|last3=Javaugue|first3=Vincent|last4=Szalat|first4=Raphael|last5=El Karoui|first5=Khalil|last6=Caulier|first6=Alexis|last7=Knebelmann|first7=Bertrand|last8=Jaccard|first8=Arnaud|last9=Chevret|first9=Sylvie|date=2015-11|title=Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease|url=https://pubmed.ncbi.nlm.nih.gov/26176826|journal=Kidney International|volume=88|issue=5|pages=1135–1143|doi=10.1038/ki.2015.201|issn=1523-1755|pmid=26176826}}</ref> | *Survival improves with early diagnosis and proteasome inhibitor (PI)-based treatment, autologous stem cell transplantation, and kidney transplantation<ref name=":5">{{Cite journal|last=Sayed|first=Rabya H.|last2=Wechalekar|first2=Ashutosh D.|last3=Gilbertson|first3=Janet A.|last4=Bass|first4=Paul|last5=Mahmood|first5=Shameem|last6=Sachchithanantham|first6=Sajitha|last7=Fontana|first7=Marianna|last8=Patel|first8=Ketna|last9=Whelan|first9=Carol J.|date=2015-12-24|title=Natural history and outcome of light chain deposition disease|url=https://pubmed.ncbi.nlm.nih.gov/26392598|journal=Blood|volume=126|issue=26|pages=2805–2810|doi=10.1182/blood-2015-07-658872|issn=1528-0020|pmc=4732758|pmid=26392598}}</ref><ref name=":6">{{Cite journal|last=Cohen|first=Camille|last2=Royer|first2=Bruno|last3=Javaugue|first3=Vincent|last4=Szalat|first4=Raphael|last5=El Karoui|first5=Khalil|last6=Caulier|first6=Alexis|last7=Knebelmann|first7=Bertrand|last8=Jaccard|first8=Arnaud|last9=Chevret|first9=Sylvie|date=2015-11|title=Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease|url=https://pubmed.ncbi.nlm.nih.gov/26176826|journal=Kidney International|volume=88|issue=5|pages=1135–1143|doi=10.1038/ki.2015.201|issn=1523-1755|pmid=26176826}}</ref> | ||
*Poor prognosis markers include old age, the presence of PCM, extrarenal (especially cardiac) involvement, poor response to initial treatment<ref name=":1" /><ref>{{Cite journal|last=Angel-Korman|first=Avital|last2=Stern|first2=Lauren|last3=Angel|first3=Yoel|last4=Sarosiek|first4=Shayna|last5=Menn-Josephy|first5=Hanni|last6=Francis|first6=Jean|last7=Ghai|first7=Sandeep|last8=Sloan|first8=J. Mark|last9=Sanchorawala|first9=Vaishali|date=2020-04|title=The Role of Kidney Transplantation in Monoclonal Ig Deposition Disease|url=https://pubmed.ncbi.nlm.nih.gov/32274452|journal=Kidney International Reports|volume=5|issue=4|pages=485–493|doi=10.1016/j.ekir.2020.01.011|issn=2468-0249|pmc=7136323|pmid=32274452}}</ref> | *Poor prognosis markers include old age, the presence of PCM, extrarenal (especially cardiac) involvement, poor response to initial treatment<ref name=":1" /><ref>{{Cite journal|last=Angel-Korman|first=Avital|last2=Stern|first2=Lauren|last3=Angel|first3=Yoel|last4=Sarosiek|first4=Shayna|last5=Menn-Josephy|first5=Hanni|last6=Francis|first6=Jean|last7=Ghai|first7=Sandeep|last8=Sloan|first8=J. Mark|last9=Sanchorawala|first9=Vaishali|date=2020-04|title=The Role of Kidney Transplantation in Monoclonal Ig Deposition Disease|url=https://pubmed.ncbi.nlm.nih.gov/32274452|journal=Kidney International Reports|volume=5|issue=4|pages=485–493|doi=10.1016/j.ekir.2020.01.011|issn=2468-0249|pmc=7136323|pmid=32274452}}</ref> | ||
*Elimination or reduction of the underlying B-cell proliferative neoplasms to control the aberrant Ig deposition is crucial for preventing disease progression<ref name=":6" /><ref name=":5" /> | *Elimination or reduction of the underlying B-cell proliferative neoplasms to control the aberrant Ig deposition is crucial for preventing disease progression<ref name=":6" /><ref name=":5" /> | ||
| Line 508: | Line 390: | ||
(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span> <references /> | (use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span> <references /> | ||
<br /> | |||
==Notes== | ==Notes== | ||
| Line 517: | Line 399: | ||
<nowiki>*</nowiki>''Citation of this Page'': “Monoclonal immunoglobulin deposition disease”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Monoclonal_immunoglobulin_deposition_disease</nowiki>. | <nowiki>*</nowiki>''Citation of this Page'': “Monoclonal immunoglobulin deposition disease”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Monoclonal_immunoglobulin_deposition_disease</nowiki>. | ||
[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases M]] | [[Category:HAEM5]] | ||
[[Category:DISEASE]] | |||
[[Category:Diseases M]] | |||